ORLANDO, FL, December 14, 2022 (GLOBE NEWSWIRE) — AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC: AVMR), a medical robotics software and artificial intelligence company, announced that it has made further progress in completing its acquisition through merger of CardioVentures, Inc. (“CardioVentures”), as previously reported in its most recent report on Form 8-K filed with SEC on November 7, 2022.

CardioVentures holds an indirect controlling interest in an Indian limited liability company (“SSI India“). SSI-India is engaged in the development, commercialization, manufacture and sale of medical and surgical robotic systems utilizing patents, trademarks and other intellectual property. It has received full clinical approval from Indian regulators and is now ready to take and ship orders for its Mantra robotic surgical system India and in over 54 other countries. Because of what the company believes to be superior functionality and ergonomics, the Mantra 2 can cost up to half less than systems from its direct competitors. The first deliveries started in Aug 2022 in Delhi In the Rajiv Gandhi Cancer Institute and Research Center and the Mantra 2 system is now operating in 3 hospitals. SSI-India plans to begin searching US FDA and European CE approvals in early 2023. The Mantra 2 System is a soft tissue-based robotic surgical system that the Company believes will have broad applications in urology, gynaecology, thoracic, head and neck and general surgery. In addition, we anticipate that the system will be the first of its kind specifically tailored to support the performance of all complex cardiac surgeries.

Upon completion of the merger, the company will change its name to SS Innovations International, Inc. and CardioVentures shareholders will become the Company’s controlling shareholders. Post-merger, we intend to focus a significant portion of our efforts on growing and advancing the business of SSI-India, which will be an indirect majority-owned subsidiary of the Company.

Around AVRA Medical Robotics

AVRA Medical Robotics, Inc.(OTC: AVMR) is a medical software and artificial intelligence company developing a fully autonomous medical robotic system that combines artificial intelligence, machine learning and proprietary software.

It empowers physicians and surgical practices through the use of software and artificial intelligence.

AVRA focuses its research and development efforts on meeting the increasing expectations of patients and physicians for the precision, efficiency and safety offered by robotics, artificial intelligence and proprietary software combined with proven medical devices and surgical instruments.

For more information, visit AVRA’s website at www.avramedical.com.

Forward-Looking Statements

This press release may contain statements that are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “assume”, “believe”, “estimate”, “expect”, “will”, “intend”, “may”, “plan”, “project”, “should”, “could”, “aim,” “designed,” “potential,” “forecast,” “goal,” “goal,” “goal,” or the negative of such terms, or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to differ materially from future results, level of activity or performance or achievements expressed or implied by these forward-looking statements.

Contact: [email protected]

Primary logo

Source: AVRA Medical Robotics, Inc.

2022 GlobeNewswire, Inc., Source press releases